Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6)

Virology

Volumn 420, Issue 1, 2011, Pages 10-19

  Xie, Qing ^a   Lerch, Thomas F ^a   Meyer, Nancy L ^a   Chapman, Michael S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antibody; Crystal; Gene therapy; Parvovirus; Receptor; Structure

Indexed keywords

ARGININE; HEPARIN; LYSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A20; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 6; ARTICLE; CONTROLLED STUDY; ENZYME LOCALIZATION; EPITOPE MAPPING; HUMAN; HUMAN CELL; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; SEROTYPE; STATIC ELECTRICITY; VIRUS CAPSID; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION;

CAPSID PROTEINS; CRYSTALLOGRAPHY, X-RAY; DEPENDOVIRUS; HELA CELLS; HUMANS; PARVOVIRIDAE INFECTIONS; PROTEIN BINDING; RECEPTORS, VIRUS; SURFACE PROPERTIES;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2; MIRIDAE; PARVOVIRUS;

EID: 80053386167     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.08.011     Document Type: Article

References (60)

1. Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.W., Kapral G.J., Grosse-Kunstleve R.W., McCoy A.J., Moriarty N.W., Oeffner R., Read R.J., Richardson D.C., Richardson J.S., Terwilliger T.C., Zwart P.H. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010, 66(Pt 2):213-221.
2. Agbandje-McKenna M., Chapman M.S. Correlating structure with function in the viral capsid. Parvoviruses 2006, 124-139. Hodder Arnold, Ltd., London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
3. Badger J., Minor I., Kremer M., Oliveira M., Smith T.J., Griffith J.P., Guerin D.M., Krishnaswarmy S., Luo M., Rossmann M.G., McKinlay M., Diana G., Dutko F.J., Fancher M., Rueckert R., Heinz B.A. Structural Analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:3304-3308.
4. Baker N.A., Sept D., Joseph S., Holst M.J., McCammon J.A. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(18):10037-10041.
5. Berns K.I. Parvoviridae: the viruses and their replication. Virology 1996, 1017-1041. Raven, Philadelphia. 3rd ed. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
6. Blacklow N.R., Hoggan M.D., Rowe W.P. Serologic evidence for human infection with adenovirus-associated viruses. J. Natl. Cancer Inst. 1968, 40(2):319-327.
7. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.-S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., Warren G.L. Crystallography and NMR system: a new software system for macromolecular structure determination. Acta Crystallogr. 1998, D54:905-921.
8. Calcedo R., Vandenberghe L.H., Gao G., Lin J., Wilson J.M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 2009, 199(3):381-390.
9. Carter B.J. Adeno-associated virus vectors in clinical trials. Hum. Gene Ther. 2005, 16(5):541-550.
10. Carter B.J. Adeno-associated virus vectors and biology of gene delivery. Parvoviruses 2006, 497-498. Hodder Arnold, Ltd., London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
11. Carter B.J. Clinical development with adeno-associated virus vectors. Parvoviruses 2006, 499-510. Hodder Arnold, Ltd., London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
12. Chapman M.S. Restrained real-space macromolecular atomic refinement using a new resolution-dependent electron density function. Acta Crystallogr. 1995, A51:69-80.
13. Chapman M.S., Agbandje-McKenna M. Atomic structure of viral particles. Parvoviruses 2006, 107-123. Hodder Arnold, Ltd., London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
14. Chapman M.S., Liljas L. Structural folds of viral proteins. Adv. Protein Chem. 2003, 64:125-196.
15. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr. 1994, D50:760-763. Collaborative Computational Project Number 4.
16. DeLano W.L. The PyMOL Molecular Graphics System 2002, DeLano Scientific, San Carlos, CA, USA.
17. Dudek T., Knipe D.M. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006, 344(1):230-239.
18. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60(Pt 12 Pt 1):2126-2132.
19. Fabiola F., Korostelev A., Chapman M.S. Bias in cross-validated free R factors: mitigation of the effects of non-crystallographic symmetry. Acta Crystallogr. D Biol. Crystallogr. 2006, 62(Pt 3):227-238.
20. Gao G., Vandenberghe L.H., Alvira M.R., Lu Y., Calcedo R., Zhou X., Wilson J.M. Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. 2004, 78(12):6381-6388.
21. Gao G., Lu Y., Calcedo R., Grant R.L., Bell P., Wang L., Figueredo J., Lock M., Wilson J.M. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol. Ther. 2005, 13(1):77-87.
22. Gerlach B., Kleinschmidt J.A., Bottcher B. Conformational changes in adeno-associated virus type 1 induced by genome packaging. J. Mol. Biol. 2011, 409(3):427-438.
23. Govindasamy L., Padron E., McKenna R., Muzyczka N., Kaludov N., Chiorini J.A., Agbandje-McKenna M. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 2006, 80(23):11556-11570.
24. Halbert C.L., Standaert T.A., Aitken M.L., Alexander I.E., Russell D.W., Miller A.D. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J. Virol. 1997, 71(8):5932-5941.
25. Halbert C.L., Standaert T.A., Wilson C.B., Miller A.D. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J. Virol. 1998, 72(12):9795-9805.
26. Halbert C.L., Allen J.M., Miller A.D. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J. Virol. 2001, 75(14):6615-6624.
27. Hermens W.T., ter Brake O., Dijkhuizen P.A., Sonnemans M.A., Grimm D., Kleinschmidt J.A., Verhaagen J. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum. Gene Ther. 1999, 10(11):1885-1891.
28. Johnson F.B. Parvovirus proteins. The Parvovirses 1984, 259. Plenum, New York. K.I. Berns (Ed.).
29. Jones T.A., Zou J.-Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. 1991, A47:110-119.
30. Krissinel E., Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 2004, 60(Pt 12):2256-2268.
31. Kuck D., Kern A., Kleinschmidt J.A. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J. Virol. Methods 2007, 140(1-2):17-24.
32. Lerch T.F., Xie Q., Chapman M.S. The structure of adeno-associated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion. Virology 2010, 403:25-36.
33. Lochrie M.A., Tatsuno G.P., Christie B., McDonnell J.W., Zhou S., Surosky R., Pierce G.F., Colosi P. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 2006, 80(2):821-834.
34. Louboutin J.P., Wang L., Wilson J.M. Gene transfer into skeletal muscle using novel AAV serotypes. J. Gene Med. 2005, 7(4):442-451.
35. Manning W.C., Paliard X., Zhou S., Pat Bland M., Lee A.Y., Hong K., Walker C.M., Escobedo J.A., Dwarki V. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J. Virol. 1997, 71(10):7960-7962.
36. Mitchell D.A., O'Donnell J., Hare J.T., Chapman M.S. Serotype-specific detection of adeno-associated virus during laboratory preparation. J. Virol. Methods 2006, 136(1-2):277-282.
37. Nam H.J., Lane M.D., Padron E., Gurda B., McKenna R., Kohlbrenner E., Aslanidi G., Byrne B., Muzyczka N., Zolotukhin S., Agbandje-McKenna M. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 2007, 81(22):12260-12271.
38. Ng R., Govindasamy L., Gurda B.L., McKenna R., Kozyreva O.G., Samulski R.J., Parent K.N., Baker T.S., Agbandje-McKenna M. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J. Virol. 2010, 84(24):12945-12957.
39. O'Donnell J., Taylor K.A., Chapman M.S. Adeno-associated virus-2 and its primary cellular receptor-Cryo-EM structure of a heparin complex. Virology 2009, 385:434-443.
40. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
41. Parks W., Boucher D., Melnick J., Taber L., Yow M. Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses. Infect. Immun. 1970, 2:716-722.
42. Rabinowitz J.E., Rolling F., Li C., Conrath H., Xiao W., Xiao X., Samulski R.J. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 2002, 76(2):791-801.
43. Rutledge E., Halbert C., Russell D. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 1998, 72(1):309-319.
44. Schmidt M., Voutetakis A., Afione S., Zheng C., Mandikian D., Chiorini J.A. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 2008, 82(3):1399-1406.
45. Su H., Yeghiazarians Y., Lee A., Huang Y., Arakawa-Hoyt J., Ye J., Orcino G., Grossman W., Kan Y.W. AAV serotype 1 mediates more efficient gene transfer to pig myocardium than AAV serotype 2 and plasmid. J. Gene Med. 2008, 10(1):33-41.
46. Summerford C., Samulski R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 1998, 72(2):1438-1445.
47. Tong L., Rossmann M.G. Rotation function calculations with GLRF program. Methods Enzymol. 1997, 276:594-611.
48. Tsao J., Chapman M.S., Agbandje M., Keller W., Smith K., Wu H., Luo M., Smith T.J., Rossmann M.G., Compans R.W., et al. The three-dimensional structure of canine parvovirus and its functional implications. Science 1991, 251(5000):1456-1464.
49. Wang Z., Zhu T., Qiao C., Zhou L., Wang B., Zhang J., Chen C., Li J., Xiao X. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 2005, 23(3):321-328. (Epub 2005 Feb 27).
50. Weger S., Wistuba A., Grimm D., Kleinschmidt J.A. Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and rep proteins. J. Virol. 1997, 71(11):8437-8447.
51. Wistuba A., Weger S., Kern A., Kleinschmidt J.A. Intermediate of adeno-associated virus Type 2 assembly: identification of soluble complexes containing rep and cap proteins. J. Virol. 1995, 69:5311-5319.
52. Wobus C.E., Hugle-Dorr B., Girod A., Petersen G., Hallek M., Kleinschmidt J.A. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 2000, 74(19):9281-9293.
53. Wu P., Xiao W., Conlon T., Hughes J., Agbandje-McKenna M., Ferkol T., Flotte T., Muzyczka N. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 2000, 74(18):8635-8647.
54. Wu Z., Asokan A., Grieger J.C., Govindasamy L., Agbandje-McKenna M., Samulski R.J. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus (AAV) serotypes. J. Virol. 2006, 80(22):11393-11397.
55. Wu Z., Asokan A., Samulski R.J. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 2006, 14(3):316-327.
56. Wu Z., Miller E., Agbandje-McKenna M., Samulski R.J. Alpha2,3 and alpha2,6N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 2006, 80(18):9093-9103.
57. Xie Q., Bu W., Bhatia S., Hare J., Somasundaram T., Azzi A., Chapman M.S. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(16):10405-10410.
58. Xie Q., Hare J., Turnigan J., Chapman M.S. Large-scale production, purification and crystallization of wild-type adeno-associated virus-2. J. Virol. Methods 2004, 122(1):17-27.
59. Xie Q., Ongley H.M., Hare J., Chapman M.S. Crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 6. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2008, 64(Pt 11):1074-1078.
60. Xin K.Q., Urabe M., Yang J., Nomiyama K., Mizukami H., Hamajima K., Nomiyama H., Saito T., Imai M., Monahan J., Okuda K., Ozawa K. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum. Gene Ther. 2001, 12(9):1047-1061.